Home › Cancro al rene › New York › New York City
Studi clinici su Cancro al rene a New York City, NY
15 studi su Cancro al rene cercano partecipanti presso sedi a New York City e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
In reclutamentoFase 1
- Research Site, New York
- Research Site, New York
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
In reclutamentoFase 1
- NEO-811 NYC Site, New York
A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
In reclutamentoFase 3
- Research Site, New York
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
In reclutamentoStudio osservazionale
- NYU Langone Medical Center, New York
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
In reclutamentoFase 1/2
- Icahn School of Medicine at Mount Sinai, New York
- Evelyn H. Lauder Breast and Imaging Center (BAIC), New York
- Memorial Sloan Kettering Cancer Center - Main Campus, New York
- e altri 1
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
In reclutamentoFase 1
- Memorial Sloan Kettering Cancer Center, New York
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
In reclutamentoFase 1
- Xencor Investigative Site, New York
- Xencor Investigative Site, New York
A Study of a Side Effects and Resource Navigation Program for People With Cancer
In reclutamento
- City College of New York (Data Collection AND Specimen Analysis), New York
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Brodalumab in the Treatment of Immune-Related Adverse Events
In reclutamentoFase 1
- Columbia University Irving Medical Center, New York
Kidney Cancer DNA Registry
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
In reclutamentoStudio osservazionaleVolontari sani benvenuti
- Memorial Sloan Kettering Cancer Center, New York
Decision Aid (DA) for Renal Patients
In reclutamento
- NYU Langone Health, New York
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, New York
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
In reclutamentoFase 1/2
- NYU Langone Health, New York
Studi su Cancro al rene in altre città
- Boston, MA12 studi
- Nashville, TN12 studi
- Houston, TX10 studi
- San Diego, CA9 studi
- Dallas, TX9 studi
- St. Louis, MO9 studi
- Washington, DC9 studi
- Seattle, WA8 studi
- Edison, NJ8 studi
- Miami, FL8 studi
- Los Angeles, CA7 studi
- Rochester, MN7 studi
Altri studi a New York City
- Cancro al seno136 studi
- Cancro del polmone non a piccole cellule121 studi
- Cancro (tutti i tipi)109 studi
- Cancro alla prostata103 studi
- Cancro metastatico93 studi
- Cancro colorettale78 studi
- Cancro ovarico69 studi
- Cancro ai polmoni60 studi
- Mieloma multiplo60 studi
- Cancro pancreatico60 studi
- Cancro dell'endometrio52 studi
- Leucemia mieloide acuta51 studi
Fonte: ClinicalTrials.gov, dati recuperati il 6 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.